Phase II Study of Pembrolizumab in Advanced Rare Cancers Shows Promise

Favorable toxicity profiles and antitumor activity seen in this phase II study of pembrolizumab supports further evaluation of the drug in this patient population.

Source: CancerNetwork - March 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news